CORE--CLINICAL BIOCHEMISTRY FACILITY

临床生化机构的目的是提供质量- 临床化学和生化流行病学的对照分析， CCSG支持的AHF科学家。该机构由一名机构负责人组成， 小约翰·P·里奇博士实验室主管史蒂文·科洛西莫理学硕士一 临床化学家，塔拉博南诺，B.S.还有一位临床协调员朱莉 Heidbrink-Fallon，文学士该设施的主要资源包括 约翰逊和约翰逊Vitros 500大型临床化学分析仪， 几台便携式临床化学分析仪Dynatech 5000 96孔板 配备Biolinx软件的读数器、闪烁计数器、HPLC、GC 自动分析仪和自动血液分析仪。该设施提供 常规临床化学测定和免疫测定以及专门的 生物化学和生物标志物测试使用收费机制。在 此外，该设施还参与生物标志物的开发，用于 大规模的人类研究。该设施为所有 CCSG支持的程序，以及非编程对齐的 AHF和其他设施内的程序。大约10-15人， AHF的受资助研究人员以及12-18名外部科学家利用 每年对设施进行约6，000至10，000次采样 每年检测。在过去一年中，该设施总使用量的63% 是由同行评审的NIH或ACS资助的项目。现有供资 在周期内，我们计划扩大该设施的能力，以包括 血液学分析和人体研究正在进行中，并计划在 AHFCC以及支持AHFCC内部正在进行的研究， 以支持研究动物机构内正在进行的研究。在 此外，为了协助实施人类调查，我们计划 提供临床协调和生物样本方面的专业知识 收集和银行。AHFCC内部的这种新专业知识至关重要 人类研究的实施，特别是在内勒达纳 研究所的需求明显增加。特别 重要的是，该设施将提供协助保密 特别是在涉及DNA分析的人类研究中。

The purpose of the Clinical Biochemistry Facility is to provide quality- controlled analyses for clinical chemistry and biochemical epidemiology to CCSG-supported AHF scientists. The facility is staffed by a facility head, John P. Richie, Jr., Ph.D. a lab supervisor, Steven Colosimo, M.S. a clinical chemist, Tara Bonanno, B.S. and a clinical coordinator, Julie Heidbrink-Fallon, B.A. The major resources of the facility include a Johnson & Johnson Vitros 500 Mainframe Clinical Chemistry Analyzer, several portable clinical chemistry analyzers Dynatech 5000 96 well plate reader with Biolinx software, scintillation counters, HPLCs, GC, autoanalyzers and a automate hematological analyzer. The facility offers routine clinical chemistry assays and immunoassays as well as specialized biochemistry and biomarker tests using a charge-back mechanism. In addition the facility is involved in biomarker development for use in large-scale human studies. This facility provides services to all of the CCSG-supported programs as well as to non-programmatically aligned programs within AHF and at other facilities. Approximately 10-15 peer- funded investigators at AHF as well as 12-18 external scientists make use of the facility each year for a total of about 6,000 to 10,000 samples assayed per year. Over the past year, 63% of the total use of the facility was by peer-reviewed NIH-or ACS-funded projects. In the present funding cycle, we plan to expand the capabilities of the facility to include hematological analyses and human studies underway and planned within the AHFCC as well as in support of ongoing studies within the AHFCC as well as in support of ongoing studies within the Research Animal Facility. In addition, to assist in the implementation of human investigation we plan to provide expertise in clinical coordination and biological sample collection and banking. This new expertise within the AHFCC is essential for the implementation of human studies, particularly at the Naylor Dana Institute where an increasing demand is clearly evident. Of particular importance, the facility will provide assistance with confidentiality issues especially in human studies involving DNA analysis.